Healthcare Biz Recap: Amarin’s PROSPECTS, Lincare Waits for PROPOSAL

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Shares of Amarin Pharmaceuticals (NASDAQ:AMRN) jump as U.S. patent examiners seem set to okay a line of key patents which could protect its AMR101 prescription fish oil pill from generic competition through the year 2030. Jefferies is confident of approval, restating its Buy on the shares and boost its target price from $24 to $26.

Don’t Miss: Arena SHOOTS THE MOON on Epic Approval.

Lincare Holdings (NASDAQ:LNCR) shares react in kind to reports that the company‚Äôs suitors, which includes Germany’s Linde AG (LANGF.PK) are making offers presently. The firm supplies oxygen and other respiratory services to in-home patients.

Shares of PM Synergetics (NASDAQ:SURG) soar after hours with word that it’s received FDA clearance for VersaVIT, which constitutes a vitrectomy system for the retinal surgery market.

Don’t Miss: Radar Movers: Facebook SINKS, Arena Pharma SURGES 28%.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business